COPD (chronic obstructive pulmonary disease) market booms but not without casualties:
This article was originally published in Clinica
The US chronic obstructive pulmonary disease (COPD) market is expected to grow from $1.89bn in 2001 to $2.97bn by 2008. However, inhaler manufacturers may not be among those to share in the booming market, as COPD drug manufacturers are increasingly opting for combination bronchodilators, says a new report by Frost & Sullivan. This will induce a shrinkage of the number of inhalers required to deliver multiple active ingredients, says the report, US Chronic Obstructive Pulmonary Disease Therapies.
You may also be interested in...
The UK has approved the mRNA-based vaccine just nine days after receiving the final Phase III results from Pfizer.
As the MHRA prepares to grant approval to the Oxford/AstraZeneca vaccine, Wockhardt is set to supply 100 million doses for the UK government’s own use and its WHO commitments. The company is also in talks with global vaccine developers to manufacture their COVID-19 vaccines for emerging economies
A combined final opinion on the European Chemicals Agency’s proposed microplastic restriction is expected from ECHA committees by year-end, at which point the European Commission will consider whether and when microplastic must be removed from all leave-on cosmetic products marketed in the EU.